FDA grants 510(k) approval for Cerasorb® M Dental and Cerasorb® Perio

Kleinostheim, 27 July 2005 – curasan AG - specialists in regenerative medicine - today received 510(k) approval by the FDA for Cerasorb® M Dental and Cerasorb® Perio.

Cerasorb® is a synthetic bone regeneration material that is fully resorbed by the body and replaced with autogenous bone. Cerasorb® M Dental is a second-generation product, featuring even faster resorption and bone replacement. It is used in regions exposed to lower loads and complements the classic Cerasorb® .

In addition, the company has developed a product by the name of Cerasorb® Perio, which is designed specifically for bone defects caused by periodontitis. Thus, curasan has taken a major step forward in terms of developing indication-specific Cerasorb® products.

“In autumn 2004, we introduced our own sales organisation for the US dental market. Cerasorb® M Dental and Cerasorb® Perio underline our ambitions as a leader within the field of state-of-the-art bone regeneration. Our target group will see the extension of our Cerasorb® portfolio as evidence of our commitment to the marketplace and will support our sales activities in this area,” said curasan's CEO H.D. Rössler.

Top of page Print page